Nucleus Software Exports Limited
Valuation (72/100) does the heavy lifting; financial trend (8/100) is the drag.
Buy zoneStocksWizard rates Nucleus Software Exports Limited a Sell, scoring 43/100 on our blended model. At ₹686.05 it trades below our blended DCF and relative-multiples fair value of ₹746.12, about 9% upside to that estimate — we read it as fairly valued. On 16.3x trailing earnings it sits cheaper than the Technology median of about 20.0x. It's sitting close to its 52-week low of ₹683.91. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,210 implies about 76% upside across 1 analysts. It clears 6 of 13 investability checks, with durability 59, valuation 79 and momentum 10 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹596.9.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-35.45% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell43Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.6%
- Pass: Low debt (D/E < 0.5): 0.01x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -2%
- Fail: Earnings growing: -47%
- Pass: Net margin ≥ 10%: 13.3%
- Pass: Current ratio > 1.5: 2.09
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.12
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter75.5%
- Institutions2.1%
- Public & other22.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 5.12.
Opportunities
- Trading in our value buy zone versus sector peers.
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Nucleus Software Exports Limited
Nucleus Software Exports Limited develops lending and transaction banking software for financial institutions across India, Asia, Europe, the Middle East, Africa, and Australia. Its main products include FinnOne Neo, a lending platform serving retail, corporate, and Islamic banking sectors, and FinnAxia, an integrated transaction banking solution for global receivables.
Nucleus Software Exports Limited — frequently asked questions
Is Nucleus Software Exports Limited a buy, hold or sell?
StocksWizard currently rates Nucleus Software Exports Limited (NUCLEUS) a Sell, based on a blended score of 43/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Nucleus Software Exports Limited's fair value?
Our blended DCF and relative-valuation model estimates Nucleus Software Exports Limited's fair value at about ₹746.12, versus a current price of ₹686.05 — roughly 9% upside. On that basis the stock looks fairly valued.
Is Nucleus Software Exports Limited financially healthy?
Nucleus Software Exports Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Nucleus Software Exports Limited's share price performed?
Nucleus Software Exports Limited is down 13% over three months, and last traded at ₹686.05. Past performance doesn't predict future returns.
More in Technology
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.